Maintaining bone health is important in the management of men with prostate cancer.
Patients receiving androgen deprivation therapy are at increased risk for treatment-related osteoporosis, and patients with bone metastases are at increased risk for skeletal morbidity related to debilitating skeletal-related events (SREs). Optimizing bone health in these patients includes lifestyle modifications, calcium/vitamin D supplementation, and osteoclast-targeted agents in select high-risk patients. No agent is approved for the prevention of bone metastases. Novel systemic agents have shown a beneficial effect bone by directly affecting tumor growth. Integration of these anticancer agents with osteoclast-targeted agents warrants further investigation.
Written by:
McKay RR, Taplin ME, Choueiri TK. Are you the author?
Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02215, USA.
Reference: Hematol Oncol Clin North Am. 2013 Dec;27(6):1261-83.
doi: 10.1016/j.hoc.2013.08.009
PubMed Abstract
PMID: 24188262
UroToday.com Bone Metastases Section
